PressJune 22, 2022 Numinus Applies for International Patent Filing of Psychedelics Production Process
PressJune 21, 2022 Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation
PressJune 17, 2022 U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
PressJune 16, 2022 Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
PressJune 15, 2022 Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders
PressJune 14, 2022 Filament Health Cultivates 70th Variety of Psilocybin-containing Mushrooms At Vancouver Facility
PressJune 13, 2022 Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives
PressJune 9, 2022 Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder
PressJune 8, 2022 Nova Mentis Receives Controlled Substances Export Approval From DEA For Proprietary Psilocybin Drug
PressJune 3, 2022 MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development
PressJune 3, 2022 SciSparc and Clearmind Collaboration Yields Another Patent Application for Proprietary Psychedelic Combination
PressJune 2, 2022 Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
PressJune 1, 2022 Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
PressMay 26, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
PressMay 25, 2022 PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
PressMay 24, 2022 Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
